G E Tsai
Affiliation: Harvard University
- Glutamatergic mechanisms in schizophreniaGuochuan Tsai
Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, USA
Annu Rev Pharmacol Toxicol 42:165-79. 2002..Thus, hypofunction of a subpopulation of cortico-limbic NMDA receptors may participate in the pathophysiology of schizophrenia...
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophreniaGuochuan Tsai
Laboratory of Molecular and Psychiatric Neuroscience (GT, McLean Hospital and Harvard Medical School, Boston, Massachusetts 02478, USA
Biol Psychiatry 55:452-6. 2004..Glycine transporter-1 is a novel target for the pharmacotherapy to enhance N-methyl-D-aspartate function...
- A preliminary study of D-cycloserine treatment in Alzheimer's diseaseG E Tsai
Geriatric Neurobehavioral Clinic, Massachusetts General Hospital, Charlestown, USA
J Neuropsychiatry Clin Neurosci 10:224-6. 1998..This double-blind crossover study of 15 mg D-cycloserine in Alzheimer's disease patients did not demonstrate clinical benefit. Higher medication dosage or long-term treatment may be required...
- Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawalG E Tsai
Department of Psychiatry, Massachusetts General Hospital, Boston, USA
Am J Psychiatry 155:726-32. 1998..Whether glutamatergic neurotransmission and oxidative stress are enhanced during ethanol withdrawal in humans is unknown...
- Improved cognition in Alzheimer's disease with short-term D-cycloserine treatmentG E Tsai
Geriatric Neurobehavoral Clinic, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
Am J Psychiatry 156:467-9. 1999..D-Cycloserine exhibits partial agonist activity at the glycine site of N-methyl-D-aspartate subtype glutamate receptor, facilitating activation of the receptor and improving cognition and memory...
- A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patientsDonald C Goff
Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
Psychopharmacology (Berl) 179:144-50. 2005..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less...
- The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophreniaJoseph T Coyle
Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
Psychopharmacology (Berl) 174:32-8. 2004..Thus, there is convincing evidence that the glycine modulatory site on the NMDA receptor is a valid therapeutic target for improving cognition and associated negative symptoms in schizophrenia...
- Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophreniaJoseph T Coyle
McLean Hospital, Belmont, Massachusetts 02478, USA
Ann N Y Acad Sci 1003:318-27. 2003..Thus, there is convincing evidence that hypofunction of a subset of NMDA receptors may contribute to the symptomatic features of schizophrenia...
- Ionotropic glutamate receptors as therapeutic targets in schizophreniaJoseph T Coyle
Curr Drug Targets CNS Neurol Disord 1:183-9. 2002..Preliminary results with an allosteric modulator of the AMPA subtype of glutamate receptor suggest enhanced cognitive functions in subjects treated with clozapine...
- D-serine added to clozapine for the treatment of schizophreniaG E Tsai
Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, McLean Hospital, Belmont, MA 02478, USA
Am J Psychiatry 156:1822-5. 1999..To study the difference between full and partial agonists at the NMDA receptor glycine site, the clinical effects of adding D-serine to clozapine were assessed...
- NMDA receptor function, neuroplasticity, and the pathophysiology of schizophreniaJoseph T Coyle
Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA
Int Rev Neurobiol 59:491-515. 2004
- Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapineDonald C Goff
Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
Biol Psychiatry 51:493-7. 2002....
- Elevated cerebrospinal fluid SNAP-25 in schizophreniaPeter M Thompson
Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
Biol Psychiatry 53:1132-7. 2003..In this study, we explored SNAP-25 level and clinical variables in a new group of subjects...
- Gene knockout of glycine transporter 1: characterization of the behavioral phenotypeGuochuan Tsai
Department of Psychiatry and Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, MA 02178, USA
Proc Natl Acad Sci U S A 101:8485-90. 2004....
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophreniaHsien-Yuan Lane
Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
Biol Psychiatry 60:645-9. 2006..Clozapine possesses particular efficacy, possibly related to potentiation of NMDA-mediated neurotransmission. This may contribute to the clozapine's unique clinical efficacy and refractoriness to the addition of NMDA-enhancing agents...
- Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophreniaPao Yen Lin
Department of Psychiatry, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Schizophr Res 71:353-60. 2004..These results suggested that the variations at the NT3 and the CNTF genes do not influence the schizophrenia risk, but a role in the susceptibility of subgroups of the patients cannot be excluded...
- Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in miceMarzia Martina
Departments of Cellular and Molecular Medicine, and Psychiatry, University of Ottawa, Ottawa, ON, Canada
J Physiol 563:777-93. 2005..Overall, these findings highlight the importance of GlyT1 in regulating glutamatergic neurotransmission...